echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > [quick news] Friday, December 22, 2017

    [quick news] Friday, December 22, 2017

    • Last Update: 2017-12-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At the end of 2017, the data volume of scigraph exceeded 1 billion, and the number of triples of scigraph of Springer nature has increased to more than 1 billion Most of these datasets are available free of charge and are available in an appropriate form for professionals to use their own devices to analyze downloaded datasets Scigraph integrates various information from the scientific research community, such as information about research funding institutions, research projects and grants, conferences, research institutions and publications In March this year, when the knowledge map went online, it contained 155 million pieces of information about the objects of academic concern Springer nature http:// National Institutes of health NIH) announced the lifting of the controversial ban on pathogen cultivation three years ago, and researchers will continue to use federal funds for functional cultivation of pathogens such as influenza viruses In the study of pathogen functional culture, researchers will deliberately improve the virulence or transmission ability of the virus, so as to better understand and study the methods against them However, artificial "upgraded" virus may also pose a threat to public health To this end, NIH also stressed that the research review mechanism after lifting the ban will be further upgraded, so as to improve the safety of such research and strictly control the impact of such projects on public health Nature https:// Loxo precision anti-cancer new drug application for listing Bayer company and its partner Loxo oncology company have recently submitted larotrecinib's rolling new drug application (NDA) to the US FDA Larotrectinib will be used to treat adult or child solid tumor patients carrying ntrk fusion gene Their tumors can't be removed or have metastases, they need systemic treatment, and after receiving other treatments, their symptoms continue to worsen or there is no other treatment option Larotrectinib is an oral, powerful and selective Trk inhibitor developed by Bayer and Loxo By targeting tropomyosin receptor kinase (Trk) directly, it can close the signal pathway that promotes tumor growth Larotrectinib has obtained the breakthrough treatment certification and orphan drug qualification issued by the US FDA PR News wire https:// recently, vitae industries, a start-up company in Rhode Island, USA, developed an autocomponent 3D printer can combine multiple complex drugs into one pill according to the dosage required by patients in just ten minutes At present, the standard commercial dosage of many prescription drugs is not suitable for everyone This 3D printer solves this problem and simplifies the process of pharmacy dispensing and patient medication, and improves human health through personalized treatment Digital trends https:// president's budget ban 7 scientific words lead to protests against centers for Disease Control and Prevention Prevention (CDC) recently said that seven words and phrases - diversity, rights, evidence-based, fetal, scientific, transgender and vulnerable groups - will not be used in the budget related documents to be published in February 2018 After analyzing the past four CDC budget applications, science magazine found that such policies seem to have taken effect: these words appear two-thirds less frequently in the 2018 budget application delivered to Congress by trump than in the 2017 budget finally submitted by former President Obama Rush Holt, chief executive of the American Association for the advancement of Science (AAAS), denounced the so-called rules as "Orwellian attacks on scientific integrity," "absurdity," "irrationality," and "censorship." Science http://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.